EDGAR·FLOW

Vaxcyte, Inc. — Form 8-K

Filed October 5, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 78/100
What the filing says
Vaxcyte reported positive topline results from OPUS-1, a Phase 3 trial of VAX-31 (31-valent pneumococcal conjugate vaccine) in 4,047 adults. VAX-31 met all prespecified co-primary immunogenicity endpoints across age groups (50+, 18-49), demonstrating noninferiority on 28 shared serotypes vs. PCV20/PCV21, superiority on 3 unique serotypes, and comparable safety. The company expects to submit a BLA (Biologics License Application) in 1H 2028, pending results from OPUS-2 and OPUS-3 trials (anticipated 1H 2027).
Why this rating

OPUS-1 success de-risks VAX-31's path to regulatory approval and potential market entry in a ~$12B pneumococcal vaccine market. For a ~$3.7B market-cap company, successful Phase 3 data for a lead candidate with broad coverage advantage is a major value inflection, though regulatory and commercial execution risks remain.

Tradability signal
NO TRADE

No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$88.30 ▲ 2.17%
at our read · unknown
$86.42
+10 min · unknown
$88.16 ▲ 2.01%
+30 min · unknown
$81.15 ▼ 6.10%
+1 hr · unknown
$77.06 ▼ 10.83%
+4 hrs · unknown
$73.72 ▼ 14.71%

The stock had already moved -2.12% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ PCVX · stock on Yahoo Finance ↗

See more from October 5, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.